BMO Capital Starts Regulus Therapeutics (RGLS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts RGLS Hot Sheet
Price: $8.16 --0%
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 25 | New: 16
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 25 | New: 16
Join SI Premium – FREE
BMO Capital initiates coverage on Regulus Therapeutics (NASDAQ: RGLS) with a Outperform. PT $10.00.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $5.11 yesterday.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $5.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Assumes Nkarta Inc. (NKTX) at Buy
- Jefferies Starts FMC Corp. (FMC) at Hold
- H.C. Wainwright Assumes Autolus Therapeutics plc (AUTL) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
